READ: ARW ON RNA
-
mRNA Hot Takes: Ghost Peppers & Global R&D
3/9/2026
Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 5, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to answer the (loaded) question: To do good science in the mRNA sector, should we be staying in the US?
-
The "Middle Ground" Advantage: Why Alnylam Is Betting Big On Chemoenzymatic Ligation
3/3/2026
Though conversations are picking up around this hybrid approach, we aren’t exactly known as an industry that embraces risk no-holds barred. While there are a handful of manufacturers and CDMOs who are embracing the hybrid model today, there are many more that are likely to hold out for the next-next gen approach: Fully enzymatic oligo production. However, as Alynlam’s CTO and Chief Quality Officer Tim Maines argued, embarking into the “middle ground” of enzymatic ligation is essential for garnering the step-by-step learnings needed to help us unlock even bigger manufacturing wins in the future.
-
mRNA Hot Takes: Habaneros & Headwinds
3/2/2026
Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 4, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo, Entrée Bio's Michelle Lynn Hall, & special guest star Andrew Fraley, founding & managing partner, Sunrise BioVentures, to discuss the industry's biggest missteps and how they've impacted the industry thus far. Topics discussed include the CMC morass, dealmaking nuances, educational initiatives, and more!
-
The Trough Of Disillusionment: 2026 RNA Reality Checks
2/23/2026
Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 3, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to call out the "hyped" and "not hyped enough" topics of conversation for the RNA space in 2026.
-
mRNA Hot Takes: Fighting Complacency And "Alternative Facts" In 2026
2/16/2026
Welcome to Advancing RNA’s mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 2, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to learn their wishlists of much-needed RNA developments for 2026 and to hear their take on an edited quote by Oscar Wilde: “The mRNA industry can survive everything but…?”
-
The Monster Under The Bed: Defining Potency in the mRNA Space
2/13/2026
During the CASSS mRNA Symposium last spring, a seemingly simple, straightforward question was raised: How are we defining and measuring our product’s potency? But as we already know, this is far from a straightforward question — and, dear reader, based on the resulting discussion amongst regulators and panel members, it became clear we have a lot of different definitions on what potency even is in the mRNA space.
-
mRNA Hot Takes: Building A Solid Foundation For Your RNA Company & Products
2/9/2026
Welcome to Advancing RNA's mRNA Hot Takes, the show where we talk about serious RNA things, but with a spicy twist. Here, in episode 1, Advancing RNA's ARW sits down with Radar Therapeutics' Sophia Lugo and Entrée Bio's Michelle Lynn Hall to discuss the biggest mistakes that can be made in building an mRNA therapeutics company, and much, much more.
-
A New Space Race: Reclaiming Efficiency In The mRNA Industry
1/27/2026
It goes without saying that efficiency in drug development is tantamount — especially when it comes to getting much-needed clinical data. So, when I asked Allan Shaw about the ongoing trends he anticipates seeing more of in 2026, he immediately pointed to the increasing prominence of overseas development, particularly in nations like Australia and China.
-
Money In The Bank: Why 2025's Setbacks Were The Foundation RNA Needed
1/5/2026
I saw 2025 as a year that was foundational for our efforts to learn more about the biology and function of our products. However, there were two developments in particular that, to me, encapsulated the trials, tribulations, and ultimately the success of an industry that is doing its damnedest to answer one of the biggest questions facing us: “Why RNA?”
-
Biology, Specificity, and the Rules of RNA Business Strategy In 2026
12/22/2025
Here, in part 3 of this outlook series, we continue our forward-looking conversation with Signify Bio CBO, Renee Williams, who shares why she hopes 2026 is the year we “focus in” on three important factors — namely our biology, our platforms, and our IP — and what this looks like/means strategically.